LY2090314

Descriptions

Biochem/physiol Actions

LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

LY2090314 can decrease the development of human MYCN amplified and non-amplified neuroblastoma (NB) cell lines in vitro. It has the ability to prevent the multiplication, colony formation and cell confluency of neuroblastoma.

Packaging

5, 25 mg in glass bottle

Specifications

Colour	yellow to orange
Quality Level	100
InChI key	HRJWTAWVFDCTGO-UHFFFAOYSA-N
InChI	1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16
Manufacturer	SIGMA-ALDRICH
Form	powder
Assay	≥98% (HPLC)